Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2008 3
2009 1
2010 2
2011 1
2012 2
2013 3
2014 2
2016 2
2018 1
2019 2
2020 1
2021 3
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K; GALAHAD investigators. Smith MR, et al. Lancet Oncol. 2022 Mar;23(3):362-373. doi: 10.1016/S1470-2045(21)00757-9. Epub 2022 Feb 4. Lancet Oncol. 2022. PMID: 35131040 Free PMC article. Clinical Trial.
A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors.
Thomas JS, El-Khoueiry AB, Maurer BJ, Groshen S, Pinski JK, Cobos E, Gandara DR, Lenz HJ, Kang MH, Reynolds CP, Newman EM. Thomas JS, et al. Among authors: pinski jk. Cancer Chemother Pharmacol. 2021 Apr;87(4):525-532. doi: 10.1007/s00280-020-04224-8. Epub 2021 Jan 10. Cancer Chemother Pharmacol. 2021. PMID: 33423090 Free PMC article. Clinical Trial.
Immune response to sipuleucel-T in prostate cancer.
Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI. Thara E, et al. Among authors: pinski jk. Cancers (Basel). 2012 Apr 18;4(2):420-41. doi: 10.3390/cancers4020420. Cancers (Basel). 2012. PMID: 24213318 Free PMC article.
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM Jr, Agarwal N. Goldkorn A, et al. Among authors: pinski jk. Clin Cancer Res. 2021 Apr 1;27(7):1967-1973. doi: 10.1158/1078-0432.CCR-20-3587. Epub 2021 Jan 26. Clin Cancer Res. 2021. PMID: 33500355 Free PMC article. Clinical Trial.
25 results